$11.24▴ 2.46%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-363.15MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-9.5%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Intellia Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year.
Key numbers
Valuation
EPS (TTM)$-3.53
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-597.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$66.09M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast
Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
This Stock Is Up 58% This Year. Is It too Late to Buy?
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.